| |
| |
|
| Insider
Information: |
Lawlor Augustine |
| Relationship: |
Chief Operating Officer |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
3,659,632 |
|
|
Indirect Shares
|
2,634,390 |
|
|
| Direct
Value |
$24,567 |
|
|
|
Indirect Value
|
$2,491,143 |
|
|
| Total
Shares |
6,294,022 |
|
|
| Total
Value |
$2,515,710 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -7.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Middlebrook Pharmaceuticals Corp |
MBRKQ |
10% Owner |
2003-10-22 |
3,629,973 |
2003-10-22 |
0 |
Premium* |
|
|
Human Genome Sciences Inc |
HGSI |
Director |
2012-07-30 |
0 |
|
0 |
Premium* |
|
|
Replidyne Inc |
RDYN |
Director |
2023-04-27 |
0 |
2023-04-27 |
0 |
Premium* |
|
|
Molecular Templates, Inc. |
MTEM |
10% Owner |
|
0 |
2008-08-29 |
1,470,588 |
Premium* |
|
|
Gyre Therapeutics |
GYRE |
Director |
2021-10-01 |
24,573 |
2021-10-01 |
24,215 |
Premium* |
|
|
Globeimmune Inc |
GBIM |
Director |
2016-02-22 |
0 |
2016-03-18 |
463,267 |
Premium* |
|
|
Leap Therapeutics, Inc. |
LPTX |
Chief Operating Officer |
2024-01-26 |
5,086 |
2024-01-26 |
676,320 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
81 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-02-22 |
4 |
S |
$1.43 |
$7,150 |
I/I |
(5,000) |
549,267 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-02-23 |
4 |
S |
$1.39 |
$6,950 |
I/I |
(5,000) |
544,267 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-02-24 |
4 |
S |
$1.17 |
$5,850 |
I/I |
(5,000) |
539,267 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-02-25 |
4 |
S |
$1.05 |
$5,250 |
I/I |
(5,000) |
534,267 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-02-26 |
4 |
S |
$1.00 |
$5,000 |
I/I |
(5,000) |
529,267 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-02-29 |
4 |
S |
$0.89 |
$4,450 |
I/I |
(5,000) |
524,267 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-03-01 |
4 |
S |
$0.94 |
$4,700 |
I/I |
(5,000) |
519,267 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-03-02 |
4 |
S |
$1.19 |
$11,900 |
I/I |
(10,000) |
509,267 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-03-03 |
4 |
S |
$1.15 |
$1,139 |
I/I |
(990) |
508,277 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-03-04 |
4 |
S |
$1.05 |
$5,250 |
I/I |
(5,000) |
503,277 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-03-07 |
4 |
S |
$0.99 |
$4,960 |
I/I |
(5,010) |
498,267 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-03-08 |
4 |
S |
$1.10 |
$5,500 |
I/I |
(5,000) |
493,267 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-03-10 |
4 |
S |
$1.35 |
$270 |
I/I |
(200) |
493,067 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-03-11 |
4 |
S |
$1.60 |
$26,080 |
I/I |
(16,300) |
476,767 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-03-15 |
4 |
S |
$2.05 |
$5,125 |
I/I |
(2,500) |
474,267 |
0 |
- |
|
| GBIM |
Globeimmune Inc |
Director |
– • – |
2016-03-18 |
4 |
S |
$1.55 |
$17,050 |
I/I |
(11,000) |
463,267 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
Director |
– • – |
2015-08-20 |
4 |
A |
$0.00 |
$0 |
I/I |
1,041,024 |
1,041,024 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
Director |
– • – |
2018-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
2,732 |
2,732 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
Director |
– • – |
2019-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,414 |
5,146 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
Director |
– • – |
2019-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,905 |
8,051 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
Director |
– • – |
2019-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,391 |
12,442 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
Director |
– • – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
3,166 |
15,608 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
Director |
– • – |
2020-02-25 |
4 |
S |
$6.10 |
$423,506 |
I/I |
(69,401) |
0 |
0 |
% |
|
| GYRE |
Gyre Therapeutics |
Director |
– • – |
2020-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,934 |
20,542 |
0 |
- |
|
| GYRE |
Gyre Therapeutics |
Director |
– • – |
2020-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,673 |
24,215 |
0 |
- |
|
81 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
